Scotia Capital’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Scotia Capital’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-15,268	Closed	-$23K	–	789
2018 Q2	$23K	Hold	15,268	–	–	﹤0.01%	661
2018 Q1	$23K	Sell	15,268 -3,200	-17%	-$5.59K	﹤0.01%	693
2017 Q4	$26K	Buy	18,468 +3,200	+21%	+$5.25K	﹤0.01%	705
2017 Q3	$35K	Hold	15,268	–	–	﹤0.01%	687
2017 Q2	$21K	Hold	15,268	–	–	﹤0.01%	674
2017 Q1	$33K	Sell	15,268 -6	-0%	-$23	﹤0.01%	718
2016 Q4	$67K	Sell	15,274 -5,878	-28%	-$27.9K	﹤0.01%	778
2016 Q3	$102K	Buy	21,152 +5,878	+38%	+$26.8K	﹤0.01%	751
2016 Q2	$50K	Buy	+15,274	New	+$57.6K	﹤0.01%	694

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Scotia Capital's ARLZ Position: Q3 2018 in Review

Scotia Capital sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 15,268 shares — an estimated $23K sold.

Scotia Capital first reported a position in ARLZ in Q2 2016 and held it in 9 quarters. The position peaked at $102K in Q3 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Scotia Capital reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Scotia Capital sold 15,268 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $23K.
Scotia Capital first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 9 quarters.
Scotia Capital's Aralez Pharmaceuticals Inc. position peaked at $102K in Q3 2016.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Scotia Capital's 13F filing for Q3 2018, filed 14 Nov 2018.